- |||||||||| risperidone / Generic mfg., Egis, fluoxetine / Generic mfg.
Two Cases of Brief Affective Psychosis Induced by Diet Aids (Regency S-V) - Apr 3, 2019 - Abstract #SIRS2019SIRS_89; Her symptoms disappreared in 3 days with risperidone 2mg/day after admission...He has prescribed diet medicines at the local diet clinic with Phentermine, fluoxetine, topiramate and caffeine for about 3 years...Detailed informations and cautions regarding the side effects of diet medicines must be established for customers to know about safety, efficacy and effects of diet therapy. 2
- |||||||||| risperidone / Generic mfg., Egis, olanzapine / Generic mfg., quetiapine / Generic mfg.
Immunomodulatory Effects of Antipsychotic Treatment on Gene Expression in First-Episode Psychosis (Regency S-V) - Apr 3, 2019 - Abstract #SIRS2019SIRS_37; Our results further emphasize the importance of understanding the immunomodulatory mechanisms of antipsychotic treatment, especially in terms of specific compounds, doses and duration of medication in patients with severe mental illness. Future studies should evaluate the response pre- and post-treatment, and the possible role of this inflammatory activation for the progression of psychiatric and metabolic symptoms.
- |||||||||| risperidone / generics, olanzapine / generics, clozapine / generics
Review, Journal: Decreased 5-HT2cR and GHSR1a interaction in antipsychotic drug-induced obesity. (Pubmed Central) - Mar 29, 2019 5-HT2cR antagonism by SGAs may disrupt the normal inhibitory tone on the GHSR1a, increasing orexigenic signalling. The 5-HT2cR and its interaction with the GHSR1a could serve as the basis for discovering novel approaches to preventing and treating SGA-induced obesity.
- |||||||||| risperidone / generics
Retrospective data, Journal, HEOR: Health service utilization and medical costs among patients with schizophrenia receiving long-acting injectable risperidone versus oral risperidone: a nationwide retrospective matched cohort study in Taiwan. (Pubmed Central) - Mar 29, 2019 Furthermore, compared with their counterparts in the unexposed group, patients in the exposed group had incurred higher medical costs because of costs incurred from increased utilization of outpatient service and hospital admissions, under the special context of the healthcare system in Taiwan, a single-payer universal health coverage system with low copayment rates. In summary, this study suggested that patients with schizophrenia treated with LAI risperidone had shorter lengths of stay, higher medical costs largely because of increased utilization of outpatient service and hospital admissions, compared with those who took risperidone orally.
- |||||||||| risperidone / generics, donepezil / generics
Preclinical, Journal: Stabilized Low-n Amyloid-β Oligomers Induce Robust Novel Object Recognition Deficits Associated with Inflammatory, Synaptic, and GABAergic Dysfunction in the Rat. (Pubmed Central) - Mar 27, 2019 In summary, this study suggested that patients with schizophrenia treated with LAI risperidone had shorter lengths of stay, higher medical costs largely because of increased utilization of outpatient service and hospital admissions, compared with those who took risperidone orally. Taken together the results suggest that acute administration of soluble low-n Aβo may be a useful model to study the early mechanisms involved in AD and provide us with a platform for testing novel therapeutic approaches that target the early underlying synaptic pathology.
- |||||||||| Geodon (ziprasidone) / RaQualia, Meiji Seika, Pfizer
Clinical, Journal: The effects of illness severity, cognition, and estimated antipsychotic dopamine receptor occupancy on insight into the illness in schizophrenia: An analysis of clinical antipsychotics trials of intervention effectiveness (CATIE) data. (Pubmed Central) - Mar 27, 2019 Consistent with previous literature, our results suggest that IIA is a function of illness severity in adult patients with schizophrenia. Future studies should explore whether DR occupancy mediates the relationships between IIA and illness severity, and IIA and cognitive dysfunction, in late-life schizophrenia (i.e. ≥60 years) given the effects of aging on cognition, IIA, and antipsychotic sensitivity.
- |||||||||| risperidone / generics, olanzapine / generics
Journal: Pharmacological interventions in social cognition deficits: A systematic mapping review. (Pubmed Central) - Mar 27, 2019 In the different social cognition domains, the majority of publications were focused on emotional processing or theory of mind, with few studies in other domains. Thus, this systematic mapping review shows that, even though there are increasing research activities, there are some important gaps to cover in future investigation.
- |||||||||| Edronax (reboxetine) / Pfizer
Clinical, Journal: Pharmacological Therapy in Panic Disorder: Current Guidelines and Novel Drugs Discovery for Treatment-resistant Patient. (Pubmed Central) - Mar 26, 2019 Apart for their effectiveness, the aforementioned compounds were generally well tolerated compared to the standard available pharmacotherapy drugs, indicating their potential therapeutic usefulness for ambivalent and hypervigilance patient. Further strong clinical trials will provide an ample support to these novel compounds as an alternative monotherapy for PD treatment-resistant patient.
- |||||||||| Abilify Maintena (aripiprazole depot formulation) / Otsuka, BMS, Lundbeck, Saphris (asenapine) / Allergan, Lundbeck, Meiji Seika
Journal: Korean Medication Algorithm for Bipolar Disorder 2018: Comparisons with Other Treatment Guidelines. (Pubmed Central) - Mar 26, 2019 ...Quetiapine, olanzapine and aripiprazole were the first-line AAPs for nearly all phases of bipolar disorder across guidelines...As research evidence accumulated over time, recommendations of newer AAPs (such as asenapine, cariprazine, paliperidone, lurasidine, long-acting injectable risperidone and aripiprazole once monthly) became prominent...Strong preference for combination therapy was characteristic of KMAP-BP 2018, predominantly in the treatment of psychotic mania and severe depression. Further studies were needed to address several issues identified in our review.
- |||||||||| Moban (molindone) / Impax, Latuda (lurasidone oral) / Sumitomo Dainippon, Geodon (ziprasidone) / RaQualia, Meiji Seika, Pfizer
Retrospective data, Review, Journal: Efficacy, acceptability, and tolerability of antipsychotics in children and adolescents with schizophrenia: A network meta-analysis. (Pubmed Central) - Mar 25, 2019 The highest weight gain was found for clozapine, quetiapine and olanzapine...Risperidone, haloperidol, paliperidone and olanzapine were associated with prolactin increase...Most of the comparisons are based only on one study or just on indirect evidence. Nevertheless, the available direct and indirect evidence showed that the treatment effects were similar compared to findings in adult patients with schizophrenia.
- |||||||||| Geodon (ziprasidone) / RaQualia, Meiji Seika, Pfizer
Review, Journal: Antipsychotic Use During Pregnancy and the Risk of Gestational Diabetes Mellitus: A Systematic Review. (Pubmed Central) - Mar 25, 2019 Findings from some studies suggesting a higher risk of GDM in pregnant women who were administered antipsychotic drugs were not confirmed by results of many other studies. The current evidence suggests no significant relationship between antipsychotic drugs, including second- and first-generation antipsychotics, and the risk of GDM.
- |||||||||| Trial completion date, Trial primary completion date: The Optimal Treatment for Treatment-resistant Schizophrenia (clinicaltrials.gov) - Mar 13, 2019
P=N/A, N=150, Recruiting, The publications on SGAs in Malaysia have undergone exponential growth, without evidence a saturation point. Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019
- |||||||||| Trial completion, Enrollment change, Trial completion date, Trial primary completion date: Cross-Sectional Iloperidone IVGTT (clinicaltrials.gov) - Mar 12, 2019
P=N/A, N=37, Completed, Trial completion date: Sep 2018 --> Sep 2019 | Trial primary completion date: Sep 2018 --> Sep 2019 Recruiting --> Completed | N=60 --> 37 | Trial completion date: Dec 2015 --> May 2016 | Trial primary completion date: Dec 2015 --> May 2016
- |||||||||| risperidone / Generic mfg., olanzapine / Generic mfg., quetiapine / Generic mfg.
Trial completion date, Trial primary completion date: Deprescribing Antipsychotics in Long-Term Care (clinicaltrials.gov) - Mar 8, 2019 P=N/A, N=20, Recruiting, Recruiting --> Completed | N=60 --> 37 | Trial completion date: Dec 2015 --> May 2016 | Trial primary completion date: Dec 2015 --> May 2016 Trial completion date: Dec 2018 --> Aug 2019 | Trial primary completion date: Oct 2018 --> Jan 2019
- |||||||||| Abilify Maintena (aripiprazole extended release) / Otsuka, Lundbeck
Trial completion, Enrollment change: Study of the Impact of Aripiprazole (Abilify (clinicaltrials.gov) - Feb 18, 2019 P4, N=47, Completed, Trial completion date: Jan 2019 --> Jan 2020 Recruiting --> Completed | N=80 --> 47
- |||||||||| risperidone / Generic mfg., oxycodone controlled release / Generic mfg., ziprasidone / Generic mfg.
New P1 trial: Reducing the Abuse of Opioids in Drug Users (clinicaltrials.gov) - Feb 11, 2019 P1, N=25, Not yet recruiting,
- |||||||||| Lu AF35700 / Lundbeck, Jiangsu NHWA Pharma
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Efficacy of Lu AF35700 in Patients With Early-in-disease or Late-in-disease Treatment-resistant Schizophrenia (clinicaltrials.gov) - Feb 11, 2019 P3, N=120, Terminated, Trial completion date: Aug 2019 --> Apr 2020 | Trial primary completion date: Aug 2019 --> Apr 2020 N=817 --> 120 | Trial completion date: Sep 2020 --> Feb 2019 | Active, not recruiting --> Terminated | Trial primary completion date: Sep 2020 --> Feb 2019; New data; the study was terminated based on new efficacy data from another study
- |||||||||| aripiprazole / Generic mfg., risperidone / Generic mfg.
Enrollment open: LAP01: Long-term Antipsychotic Pediatric Safety Trial (clinicaltrials.gov) - Jan 10, 2019 P=N/A, N=700, Recruiting, Recruiting --> Active, not recruiting | Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020 Not yet recruiting --> Recruiting
- |||||||||| aripiprazole / Generic mfg., risperidone / Generic mfg.
P4 data, Trial initiation date: LAP01: Long-term Antipsychotic Pediatric Safety Trial (clinicaltrials.gov) - Dec 14, 2018 P=N/A, N=700, Not yet recruiting, Not yet recruiting --> Recruiting Initiation date: Oct 2018 --> Jan 2019
- |||||||||| risperidone controlled-release implant (BB-0817) / Braeburn
Trial termination: Safety and Tolerability of Risperidone Implants (clinicaltrials.gov) - Dec 6, 2018 P3, N=140, Terminated, N=50 --> 66 | Active, not recruiting --> Terminated Active, not recruiting --> Terminated
- |||||||||| aripiprazole / Generic mfg., risperidone / Generic mfg.
P4 data, Trial initiation date: LAP01: Long-term Antipsychotic Pediatric Safety Trial (clinicaltrials.gov) - Oct 22, 2018 P=N/A, N=700, Not yet recruiting, Trial completion date: Oct 2018 --> Aug 2019 | Trial primary completion date: Oct 2018 --> Aug 2019 Initiation date: Jul 2018 --> Oct 2018
|